Takeda Has One Shot Remaining With Orteronel In Prostate Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.